These evidences provide useful information toward the development of novel therapeutic strategies for pterygium involving the use of COX-2 and survivin inhibitors alone or in combination, which might contribute to the treatment of pterygium through the suppression of the anti-apoptotic effect of survivin and the tumorigenic induction of COX-2. This evidence concerns the gene BIRC5 and pterygium.